← Back to home

LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION

Clinical trials for LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION explained in plain language.

Never miss a new study

Get alerted when new LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION trials appear

Sign up with your email to follow new studies for LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New Triple-Threat attack on rare bile duct cancer

Disease control Recruiting now

This study is testing whether adding two newer drugs (ivosidenib and durvalumab) to standard chemotherapy works better for people with advanced bile duct cancer that has a specific genetic change called IDH1 mutation. The trial will first check if the combination is safe, then se…

Matched conditions: LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION

Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION

Get alerted when new LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION trials appear

New Triple-Threat attack on rare bile duct cancer